Standard
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. / Keshav, Satish; Vaňásek, Tomáš; Niv, Yaron; Petryka, Robert; Howaldt, Stephanie; Bafutto, Mauro; Rácz, István; Hetzel, David; Nielsen, Ole Haagen; Vermeire, Séverine; Reinisch, Walter; Karlén, Per; Schreiber, Stefan; Schall, Thomas J; Bekker, Pirow.
In:
P L o S One, Vol. 8, No. 3, e60094, 2013.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Keshav, S, Vaňásek, T, Niv, Y, Petryka, R, Howaldt, S, Bafutto, M, Rácz, I, Hetzel, D
, Nielsen, OH, Vermeire, S, Reinisch, W, Karlén, P, Schreiber, S, Schall, TJ & Bekker, P 2013, '
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease',
P L o S One, vol. 8, no. 3, e60094.
https://doi.org/10.1371/journal.pone.0060094APA
Keshav, S., Vaňásek, T., Niv, Y., Petryka, R., Howaldt, S., Bafutto, M., Rácz, I., Hetzel, D.
, Nielsen, O. H., Vermeire, S., Reinisch, W., Karlén, P., Schreiber, S., Schall, T. J., & Bekker, P. (2013).
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
P L o S One,
8(3), [e60094].
https://doi.org/10.1371/journal.pone.0060094Vancouver
Keshav S, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M et al.
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
P L o S One. 2013;8(3). e60094.
https://doi.org/10.1371/journal.pone.0060094Author
Keshav, Satish ; Vaňásek, Tomáš ; Niv, Yaron ; Petryka, Robert ; Howaldt, Stephanie ; Bafutto, Mauro ; Rácz, István ; Hetzel, David ; Nielsen, Ole Haagen ; Vermeire, Séverine ; Reinisch, Walter ; Karlén, Per ; Schreiber, Stefan ; Schall, Thomas J ; Bekker, Pirow. / A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. In: P L o S One. 2013 ; Vol. 8, No. 3.
Bibtex
@article{f28f628f4c724a128509f554f64cf4b2,
title = "A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease",
author = "Satish Keshav and Tom{\'a}{\v s} Va{\v n}{\'a}sek and Yaron Niv and Robert Petryka and Stephanie Howaldt and Mauro Bafutto and Istv{\'a}n R{\'a}cz and David Hetzel and Nielsen, {Ole Haagen} and S{\'e}verine Vermeire and Walter Reinisch and Per Karl{\'e}n and Stefan Schreiber and Schall, {Thomas J} and Pirow Bekker",
year = "2013",
doi = "10.1371/journal.pone.0060094",
language = "English",
volume = "8",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "3",
}
RIS
TY - JOUR
T1 - A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease
AU - Keshav, Satish
AU - Vaňásek, Tomáš
AU - Niv, Yaron
AU - Petryka, Robert
AU - Howaldt, Stephanie
AU - Bafutto, Mauro
AU - Rácz, István
AU - Hetzel, David
AU - Nielsen, Ole Haagen
AU - Vermeire, Séverine
AU - Reinisch, Walter
AU - Karlén, Per
AU - Schreiber, Stefan
AU - Schall, Thomas J
AU - Bekker, Pirow
PY - 2013
Y1 - 2013
U2 - 10.1371/journal.pone.0060094
DO - 10.1371/journal.pone.0060094
M3 - Journal article
C2 - 23527300
VL - 8
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 3
M1 - e60094
ER -
